A Phase 2 Pilot Study to Evaluate the Safety and Activity of BB3 as an Adjunct to Percutaneous Coronary Intervention (PCI) in Subjects Presenting With Acute ST Segment Elevation Myocardial Infarction (STEMI)

Trial Profile

A Phase 2 Pilot Study to Evaluate the Safety and Activity of BB3 as an Adjunct to Percutaneous Coronary Intervention (PCI) in Subjects Presenting With Acute ST Segment Elevation Myocardial Infarction (STEMI)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2014

At a glance

  • Drugs BB 3 (Primary)
  • Indications Myocardial infarction
  • Focus Pharmacodynamics
  • Sponsors Angion Biomedica
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Oct 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 18 Jul 2012 The first patient has been treated, according to an Angion Biomedica media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top